|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
HRP20250897T1
(hr)
|
2009-05-02 |
2025-09-26 |
Genzyme Corporation |
Genska terapija za neurodegenerativne poremećaje
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
EP2561073B1
(en)
|
2010-04-23 |
2016-08-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
US9546369B2
(en)
|
2010-04-23 |
2017-01-17 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3444346B1
(en)
|
2010-04-23 |
2022-07-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP3318635A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
CN105755044A
(zh)
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
CN115120746A
(zh)
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
EP3003391B1
(en)
|
2013-05-31 |
2021-09-22 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
ES2739288T3
(es)
|
2013-09-13 |
2020-01-30 |
California Inst Of Techn |
Recuperación selectiva
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
EP3800191B1
(en)
|
2014-03-17 |
2025-08-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
CA2942515C
(en)
|
2014-03-18 |
2025-12-09 |
University Of Massachusetts |
Raav-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
LT3137497T
(lt)
|
2014-05-02 |
2021-07-26 |
Genzyme Corporation |
Aav vektoriai, skirti tinklainės ir cns genų terapijai
|
|
CA2947468C
(en)
*
|
2014-05-14 |
2022-10-25 |
Laboratorios Del Dr. Esteve S.A. |
Adenoassociated virus vectors for the treatment of lysosomal storage disorders
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
EP3200830B1
(en)
|
2014-10-03 |
2020-09-09 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
|
CR20170406A
(es)
|
2015-02-10 |
2017-11-14 |
Genzyme Corp |
Arni variante
|
|
CN107530447A
(zh)
|
2015-02-10 |
2018-01-02 |
建新公司 |
病毒颗粒至纹状体和皮质的增强递送
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US11021519B2
(en)
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
EP3268481B1
(en)
*
|
2015-03-11 |
2020-05-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Rpgr vectors for treating x-linked retinitis pigmentosa
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
RS61907B1
(sr)
|
2015-04-06 |
2021-06-30 |
Subdomain Llc |
Polipeptidi koji sadrže de novo vezujući domen i njihova primena
|
|
WO2016164642A1
(en)
|
2015-04-08 |
2016-10-13 |
The United States Of America, As Represented By The Secretary Of Health And Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
ES2865487T3
(es)
|
2015-09-28 |
2021-10-15 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores virales que evaden los anticuerpos
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
KR102423442B1
(ko)
*
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
MX2018007330A
(es)
*
|
2015-12-15 |
2019-03-14 |
Genzyme Corp |
Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii.
|
|
CA3011939A1
(en)
*
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
WO2017147477A1
(en)
*
|
2016-02-26 |
2017-08-31 |
University Of Florida Research Foundation, Inc. |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
KR102427379B1
(ko)
*
|
2016-05-18 |
2022-08-02 |
보이저 테라퓨틱스, 인크. |
헌팅톤 질환을 치료하기 위한 조성물 및 방법
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
WO2018009814A1
(en)
*
|
2016-07-08 |
2018-01-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
|
EP3485005A1
(en)
*
|
2016-07-12 |
2019-05-22 |
The University Of Manchester |
Gene therapy
|
|
AU2017302013B2
(en)
|
2016-07-29 |
2022-05-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US20190262373A1
(en)
*
|
2016-08-16 |
2019-08-29 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
IL315358A
(en)
*
|
2016-08-18 |
2024-11-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
EP3500279A4
(en)
*
|
2016-08-19 |
2020-04-22 |
Calimmune, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
|
|
JP7165410B2
(ja)
|
2016-08-19 |
2022-11-04 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド |
組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
CA3038292A1
(en)
|
2016-09-28 |
2018-04-05 |
Cohbar, Inc. |
Therapeutic mots-c related peptides
|
|
EP3518985A4
(en)
*
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
KR20190088561A
(ko)
|
2016-12-07 |
2019-07-26 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
인터류킨-1 수용체 길항제(IL-1RA) cDNA
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
US10898585B2
(en)
|
2017-04-14 |
2021-01-26 |
Ptc Therapeutics .Inc. |
Gene therapy for AADC deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
JP2020518259A
(ja)
*
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
US11859179B2
(en)
|
2017-05-09 |
2024-01-02 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (ALS)
|
|
CA3061968A1
(en)
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (aap)-dependence of viruses
|
|
EP3634978A1
(en)
|
2017-06-07 |
2020-04-15 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
CA3053154A1
(en)
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
SG11202000840YA
(en)
|
2017-07-31 |
2020-02-27 |
Reflection Biotechnologies Ltd |
Cellular models of and therapies for ocular diseases
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
US20200377887A1
(en)
*
|
2017-09-22 |
2020-12-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
CN111356763B
(zh)
|
2017-09-22 |
2024-03-12 |
建新公司 |
变体RNAi
|
|
US12043848B2
(en)
*
|
2017-10-16 |
2024-07-23 |
Vigeneron Gmbh |
AAV vectors
|
|
CN111867635A
(zh)
*
|
2017-10-20 |
2020-10-30 |
法国国家卫生及研究医学协会 |
包括视网膜下递送治疗有效量的重组aav9衍生载体的在对象的视锥细胞光感受器中表达目的多核苷酸的方法
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
KR20250070609A
(ko)
|
2017-11-14 |
2025-05-20 |
아르셀엑스, 인크. |
다기능성 면역 세포 요법
|
|
MX2020005033A
(es)
*
|
2017-11-15 |
2020-10-28 |
Friedrich Miescher Institute For Biomedical Res |
Promotor especifico de las celulas del epitelio pigmentario retinal en primates.
|
|
KR102704296B1
(ko)
*
|
2017-11-15 |
2024-09-05 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
Rdh12 암호화 영역을 포함하는 바이러스 벡터 및 망막 이영양증을 치료하는 방법
|
|
CA3082450A1
(en)
|
2017-11-21 |
2019-05-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
CN112153990A
(zh)
*
|
2018-03-23 |
2020-12-29 |
纽约市哥伦比亚大学理事会 |
用于常染色体显性疾病的基因编辑
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
AU2019247748A1
(en)
|
2018-04-03 |
2020-10-08 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
EP3774852A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
MX2020011386A
(es)
|
2018-04-27 |
2021-01-29 |
Spacecraft Seven Llc |
Terapia genica para la degeneracion del snc.
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
EP3813845A4
(en)
*
|
2018-05-15 |
2022-10-26 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US20210214749A1
(en)
|
2018-05-16 |
2021-07-15 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
CN112204145B
(zh)
*
|
2018-06-01 |
2024-03-26 |
佛罗里达大学研究基金会有限公司 |
用于治疗显性视网膜色素变性的组合物和方法
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
KR102931619B1
(ko)
|
2018-08-03 |
2026-02-26 |
젠자임 코포레이션 |
알파-시뉴클레인에 대한 변이형 RNAi
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
WO2020077091A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Wisconsin Alumni Research Foundation |
Kir 7.1 gene therapy vectors and methods of using the same
|
|
AU2019357039B2
(en)
*
|
2018-10-12 |
2025-10-09 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe PKU by liver-directed gene replacement therapy
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
CA3120923A1
(en)
*
|
2018-11-26 |
2020-06-04 |
Universitat Autonoma De Barcelona |
Fibroblast growth factor 21 (fgf21) gene therapy
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
US20220089670A1
(en)
*
|
2018-12-28 |
2022-03-24 |
University Of Rochester |
Gene Therapy for BEST1 Dominant Mutations
|
|
DK3906066T5
(da)
*
|
2019-01-04 |
2024-08-05 |
Ultragenyx Pharmaceutical Inc |
Geneterapikonstruktioner til behandling af wilsons sygdom
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
EP3914229A4
(en)
*
|
2019-01-23 |
2022-11-02 |
University of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
SG11202107761SA
(en)
|
2019-01-28 |
2021-08-30 |
Cohbar Inc |
Therapeutic peptides
|
|
KR20210148101A
(ko)
|
2019-02-04 |
2021-12-07 |
프리라인 테라퓨틱스 리미티드 |
폴리뉴클레오티드
|
|
JP7597380B2
(ja)
*
|
2019-03-04 |
2024-12-10 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
|
|
AU2020233396B2
(en)
|
2019-03-04 |
2025-09-11 |
Duke University |
Compositions and methods for the diagnosis and treatment of retinopathies
|
|
JP7663504B2
(ja)
*
|
2019-03-08 |
2025-04-16 |
ユニベルシテ パリ－サクレー |
遺伝子置換による希少な眼疾患のための改善された治療方法
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
JP7664848B2
(ja)
*
|
2019-04-10 |
2025-04-18 |
プリベイル セラピューティクス，インコーポレーテッド |
リソソーム障害のための遺伝子療法
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US12491263B2
(en)
|
2019-05-13 |
2025-12-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
US20220233655A1
(en)
*
|
2019-05-17 |
2022-07-28 |
Research Institute At Nationwide Children's Hospital |
Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
|
|
WO2020251954A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for arsa gene transfer and methods of use thereof
|
|
CA3144986A1
(en)
*
|
2019-06-27 |
2020-12-30 |
University Of Florida Research Foundation, Incorporated |
Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
MX2022000551A
(es)
*
|
2019-07-15 |
2022-05-18 |
Meiragtx Uk Ii Ltd |
Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica.
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
WO2021041324A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Duke University |
Compositions and methods for the treatment of pathological pain and itch
|
|
WO2021046169A1
(en)
*
|
2019-09-03 |
2021-03-11 |
University Of Cincinnati |
Methods and compositions for the treatment of als
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4041755A4
(en)
*
|
2019-10-10 |
2023-10-25 |
Solid Biosciences Inc. |
Modified aav capsids and uses thereof
|
|
US12611436B2
(en)
|
2019-10-17 |
2026-04-28 |
Sarepta Therapeutics, Inc. |
AAV transfer cassette
|
|
JP2022551739A
(ja)
|
2019-10-17 |
2022-12-13 |
ストライドバイオ，インコーポレイテッド |
ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
|
|
WO2021081217A1
(en)
*
|
2019-10-23 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
WO2021092300A1
(en)
*
|
2019-11-08 |
2021-05-14 |
President And Fellows Of Harvard College |
Viral capsid polypeptides
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
EP4097121A1
(en)
*
|
2020-01-29 |
2022-12-07 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
JP2023513208A
(ja)
*
|
2020-02-07 |
2023-03-30 |
ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク |
神経変性の発症を遅延させるかまたは神経変性を処置するためのメタボロームのリプログラミング
|
|
EP4107169A4
(en)
*
|
2020-02-18 |
2024-07-17 |
The University of North Carolina at Chapel Hill |
CAPSID-AAV PROMOTER INTERACTIONS AND CELL SELECTIVE GENE EXPRESSION
|
|
EP4110913A4
(en)
*
|
2020-02-28 |
2024-07-24 |
University of Massachusetts |
OLIGONUCLEOTIDES FOR PRNP MODULATION
|
|
EP4117644A4
(en)
|
2020-03-11 |
2024-08-14 |
Massachusetts Eye and Ear Infirmary |
GENE THERAPY FOR NMNAT1-ASSOCIATED RETINAL DEGENERATION
|
|
WO2021202494A1
(en)
*
|
2020-03-31 |
2021-10-07 |
University Of Massachusetts |
Aav capsids variants and uses thereof
|
|
JP2023523573A
(ja)
*
|
2020-04-14 |
2023-06-06 |
ジェネトン |
酸性セラミダーゼ欠乏症を処置するためのベクター
|
|
JP7713956B2
(ja)
|
2020-04-15 |
2025-07-28 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
TWI900553B
(zh)
|
2020-05-13 |
2025-10-11 |
美商航海家醫療公司 |
Aav蛋白殼之趨性重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
WO2021252989A2
(en)
*
|
2020-06-13 |
2021-12-16 |
Oculogenex Inc. |
Aav-mediated gene transfer for retinopathy
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
KR20230042468A
(ko)
|
2020-08-05 |
2023-03-28 |
스페이스크래프트 세븐, 엘엘씨 |
Csrp3 (시스테인 및 글리신 풍부 단백질 3) 유전자 요법
|
|
KR20230043869A
(ko)
|
2020-08-07 |
2023-03-31 |
스페이스크래프트 세븐, 엘엘씨 |
Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
|
|
AU2021328475A1
(en)
*
|
2020-08-19 |
2023-03-16 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of Rett syndrome
|
|
CA3191543A1
(en)
*
|
2020-09-04 |
2022-03-10 |
Lei Cao |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
JP2024507860A
(ja)
*
|
2021-02-22 |
2024-02-21 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
眼病態に対するウイルスベクターベースの遺伝子療法
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
CA3216809A1
(en)
*
|
2021-04-26 |
2022-11-03 |
Brendan BEAHM |
Compositions and methods for treating ngyl1 deficiency
|
|
US20240316219A1
(en)
*
|
2021-05-03 |
2024-09-26 |
North Carolina State University |
Compositions and methods related to the treatment of ocular diseases in equines
|
|
EP4399314A4
(en)
*
|
2021-09-06 |
2025-09-10 |
Huidagene Therapeutics Singapore Pte Ltd |
TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
US20250213727A1
(en)
*
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
EP4511482A4
(en)
*
|
2022-04-19 |
2026-03-18 |
Shanghai Vitalgen Biopharma Co Ltd |
Recombinant AAV vectors for the treatment of neurodegenerative disorders
|
|
WO2023212521A2
(en)
*
|
2022-04-25 |
2023-11-02 |
Myrtelle Inc. |
Treatments of disorders of myelin
|
|
EP4514949A1
(en)
|
2022-04-25 |
2025-03-05 |
Hadasit Medical Research Services&Development Ltd. |
Methods and compositions for treating vision loss
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
EP4551253A1
(en)
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
JP2025524636A
(ja)
*
|
2022-07-12 |
2025-07-30 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
アデノ随伴ウイルス遺伝子療法産物及び方法
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4698206A1
(fr)
|
2023-04-21 |
2026-02-25 |
PulseSight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
TW202547561A
(zh)
|
2024-01-25 |
2025-12-16 |
美商健臻公司 |
基於ｆｕｓ向大腦遞送病毒顆粒之方法
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
CN120829932A
(zh)
*
|
2024-04-18 |
2025-10-24 |
临港国家实验室 |
治疗眼部疾病的药物组合物及方法
|